Stephanie A. Christenson, MD, MAS - Targeting Eosinophils for Fewer Exacerbations: The Future of Biologic Treatments in COPD Management
CME in Minutes: Education in Cardiology & Pulmonology09/20/24 • 14 min
Please visit answersincme.com/PES860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary disease discusses the implications of the latest evidence on biologic therapies targeting type 2 inflammation for the treatment of chronic obstructive pulmonary disease (COPD). Upon completion of this activity, participants should be better able to: Identify the rationale for investigating biologics targeting type 2 inflammation for the treatment of patients with chronic obstructive pulmonary disease (COPD); Review the clinical impact of emerging biologics in the treatment of eosinophilic COPD in patients at high risk of exacerbations; Outline strategies to implement biologics targeting type 2 eosinophilic inflammation into clinical practice, as they become available. This activity is intended for US healthcare professionals only.
09/20/24 • 14 min
Generate a badge
Get a badge for your website that links back to this episode
Select type & size
<a href="https://goodpods.com/podcasts/cme-in-minutes-education-in-cardiology-and-pulmonology-474877/stephanie-a-christenson-md-mas-targeting-eosinophils-for-fewer-exacerb-74227946"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to stephanie a. christenson, md, mas - targeting eosinophils for fewer exacerbations: the future of biologic treatments in copd management on goodpods" style="width: 225px" /> </a>
Copy